𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Pharmacokinetics and pharmacodynamics of levodopa

✍ Scribed by John G. Nutt

Publisher
John Wiley and Sons
Year
2008
Tongue
English
Weight
68 KB
Volume
23
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.

✦ Synopsis

The pharmacokinetics and pharmacodynamics of levodopa are dominated by two features: the short plasma half-life of the drug and the portion of the antiparkinsonian response that parallels the plasma levodopa levels, the socalled short-duration response. These features are the basis of motor fluctuations that complicate long-term therapy with levodopa. Motor fluctuations will predictably improve with measures that prolong the elevations of plasma levodopa or prolong the efficacy of dopamine synthesized from exogenous levodopa. Because dyskinesia is closely linked to the shortduration response and conceivably part of the short-duration response, it is less clear that dyskinesia will be improved by therapeutic strategies that reduce motor fluctuations.

📜 SIMILAR VOLUMES

The effect of exercise on pharmacokineti
The effect of exercise on pharmacokinetics and pharmacodynamics of levodopa
✍ I. Reuter; S. Harder; M. Engelhardt; H. Baas 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 135 KB 👁 1 views

The aim of our study was to evaluate the influence of low-intensity exercise on levodopa absorption and levodopa motor effect. We studied the pharmacokinetics and pharmacodynamics of levodopa under resting conditions and under a workload of 50 watts for 2 hours on a cycle ergometer in 12 parkinsonia

Genetic polymorphism of catechol-O-methy
Genetic polymorphism of catechol-O-methyltransferase and levodopa pharmacokinetic–pharmacodynamic pattern in patients with Parkinson's disease
✍ Manuela Contin; Paolo Martinelli; Mirella Mochi; Roberto Riva; Fiorenzo Albani; 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 195 KB

## Abstract We explored the potential effect of catechol‐__O__‐methyltransferase (COMT) genetic polymorphism on the pharmacokinetics and pharmacodynamics of a standard oral dose of levodopa in patients with Parkinson's disease (PD). We prospectively collected blood samples for COMT genotyping from

Safety of entacapone and apomorphine coa
Safety of entacapone and apomorphine coadministration in levodopa-treated Parkinson's disease patients: Pharmacokinetic and pharmacodynamic results of a multicenter, double-blind, placebo-controlled, cross-over study
✍ Jan C.M. Zijlmans; Berengere Debilly; Olivier Rascol; Andrew J. Lees; Franck Dur 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 146 KB 👁 1 views

## Abstract We investigated whether administration of the catechol‐__O__‐methyl transferase (COMT) inhibitor entacapone, at doses of 200 mg and 400 mg, alters the pharmacokinetics of apomorphine in Parkinson's disease patients experiencing severe motor fluctuations. In addition, the pharmacodynamic

Pharmacokinetic-pharmacodynamic crossove
Pharmacokinetic-pharmacodynamic crossover comparison of two levodopa extension strategies
✍ Peter A. LeWitt; Danna Jennings; Kelly E. Lyons; Rajesh Pahwa; Adrian L. Rabinow 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 143 KB

## Abstract Controlled‐release carbidopa and levodopa (CL‐CR) and the combination of carbidopa, levodopa, and entacapone (CLE) are used for extending levodopa (L‐dopa) effects. In a randomized, open‐label crossover study of 17 PD subjects with wearing‐off responses, we compared 8‐hour L‐dopa pharma